200 related articles for article (PubMed ID: 26930533)
1. Preschool outcomes following prenatal serotonin reuptake inhibitor exposure: differences in language and behavior, but not cognitive function.
Johnson KC; Smith AK; Stowe ZN; Newport DJ; Brennan PA
J Clin Psychiatry; 2016 Feb; 77(2):e176-82. PubMed ID: 26930533
[TBL] [Abstract][Full Text] [Related]
2. Adverse outcomes following serotonin reuptake inhibitor exposure during pregnancy.
Andrade C
J Clin Psychiatry; 2016 Feb; 77(2):e199-200. PubMed ID: 26930536
[No Abstract] [Full Text] [Related]
3. School-age social behavior and pragmatic language ability in children with prenatal serotonin reuptake inhibitor exposure.
Smearman EL; Hendrix CL; Winiarski DA; Johnson KC; Smith AK; Ousley OY; Stowe ZN; Newport DJ; Brennan PA
Dev Psychopathol; 2020 Feb; 32(1):21-30. PubMed ID: 30728091
[TBL] [Abstract][Full Text] [Related]
4. Impact of prenatal exposure to serotonin reuptake inhibitors or maternal major depressive disorder on infant developmental outcomes.
Santucci AK; Singer LT; Wisniewski SR; Luther JF; Eng HF; Dills JL; Sit DK; Hanusa BH; Wisner KL
J Clin Psychiatry; 2014 Oct; 75(10):1088-95. PubMed ID: 25373117
[TBL] [Abstract][Full Text] [Related]
5. Effect of Time-Dependent Selective Serotonin Reuptake Inhibitor Antidepressants During Pregnancy on Behavioral, Emotional, and Social Development in Preschool-Aged Children.
Lupattelli A; Wood M; Ystrom E; Skurtveit S; Handal M; Nordeng H
J Am Acad Child Adolesc Psychiatry; 2018 Mar; 57(3):200-208. PubMed ID: 29496129
[TBL] [Abstract][Full Text] [Related]
6. Intra-uterine exposure to selective serotonin reuptake inhibitors (SSRIs), maternal psychopathology, and neurodevelopment at age 2.5years - Results from the prospective cohort SMOK study.
van der Veere CN; de Vries NKS; van Braeckel KNJA; Bos AF
Early Hum Dev; 2020 Aug; 147():105075. PubMed ID: 32504880
[TBL] [Abstract][Full Text] [Related]
7. Similar names, different results: Consistency of the associations between prenatal exposure to phthalates and parent-ratings of behavior problems in preschool children.
England-Mason G; Martin JW; MacDonald A; Kinniburgh D; Giesbrecht GF; Letourneau N; Dewey D
Environ Int; 2020 Sep; 142():105892. PubMed ID: 32593833
[TBL] [Abstract][Full Text] [Related]
8. Association of Selective Serotonin Reuptake Inhibitor Exposure During Pregnancy With Speech, Scholastic, and Motor Disorders in Offspring.
Brown AS; Gyllenberg D; Malm H; McKeague IW; Hinkka-Yli-Salomäki S; Artama M; Gissler M; Cheslack-Postava K; Weissman MM; Gingrich JA; Sourander A
JAMA Psychiatry; 2016 Nov; 73(11):1163-1170. PubMed ID: 27732704
[TBL] [Abstract][Full Text] [Related]
9. Infant developmental outcomes following prenatal exposure to antidepressants, and maternal depressed mood and positive affect.
Hanley GE; Brain U; Oberlander TF
Early Hum Dev; 2013 Aug; 89(8):519-24. PubMed ID: 23384962
[TBL] [Abstract][Full Text] [Related]
10. Neurodevelopmental outcomes following prenatal exposure to serotonin reuptake inhibitor antidepressants: a "social teratogen" or moderator of developmental risk?
Hanley GE; Oberlander TF
Birth Defects Res A Clin Mol Teratol; 2012 Aug; 94(8):651-9. PubMed ID: 22733632
[TBL] [Abstract][Full Text] [Related]
11. Prenatal exposure to serotonin reuptake inhibitor antidepressants and childhood behavior.
Hanley GE; Brain U; Oberlander TF
Pediatr Res; 2015 Aug; 78(2):174-80. PubMed ID: 25897539
[TBL] [Abstract][Full Text] [Related]
12. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors: literature review and implications for clinical applications.
Moses-Kolko EL; Bogen D; Perel J; Bregar A; Uhl K; Levin B; Wisner KL
JAMA; 2005 May; 293(19):2372-83. PubMed ID: 15900008
[TBL] [Abstract][Full Text] [Related]
13. Prenatal exposure to selective serotonin reuptake inhibitors and childhood overweight at 7 years of age.
Grzeskowiak LE; Gilbert AL; Sørensen TI; Olsen J; Sørensen HT; Pedersen LH; Morrison JL
Ann Epidemiol; 2013 Nov; 23(11):681-7. PubMed ID: 24113367
[TBL] [Abstract][Full Text] [Related]
14. Prenatal effects of selective serotonin reuptake inhibitor antidepressants, serotonin transporter promoter genotype (SLC6A4), and maternal mood on child behavior at 3 years of age.
Oberlander TF; Papsdorf M; Brain UM; Misri S; Ross C; Grunau RE
Arch Pediatr Adolesc Med; 2010 May; 164(5):444-51. PubMed ID: 20439795
[TBL] [Abstract][Full Text] [Related]
15. Behavior and inhibitory control in children with prenatal exposure to antidepressants and medically untreated depression.
Hermansen TK; Røysamb E; Augusti EM; Melinder A
Psychopharmacology (Berl); 2016 Apr; 233(8):1523-35. PubMed ID: 26924747
[TBL] [Abstract][Full Text] [Related]
16. Neurodevelopment of children prenatally exposed to selective reuptake inhibitor antidepressants: Toronto sibling study.
Nulman I; Koren G; Rovet J; Barrera M; Streiner DL; Feldman BM
J Clin Psychiatry; 2015 Jul; 76(7):e842-7. PubMed ID: 26231010
[TBL] [Abstract][Full Text] [Related]
17. Motor development in children prenatally exposed to selective serotonin reuptake inhibitors: a large population-based pregnancy cohort study.
Handal M; Skurtveit S; Furu K; Hernandez-Diaz S; Skovlund E; Nystad W; Selmer R
BJOG; 2016 Nov; 123(12):1908-1917. PubMed ID: 26374234
[TBL] [Abstract][Full Text] [Related]
18. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression.
Nulman I; Koren G; Rovet J; Barrera M; Pulver A; Streiner D; Feldman B
Am J Psychiatry; 2012 Nov; 169(11):1165-74. PubMed ID: 23128923
[TBL] [Abstract][Full Text] [Related]
19. Association of Poor Family Functioning From Pregnancy Onward With Preadolescent Behavior and Subcortical Brain Development.
Xerxa Y; Delaney SW; Rescorla LA; Hillegers MHJ; White T; Verhulst FC; Muetzel RL; Tiemeier H
JAMA Psychiatry; 2021 Jan; 78(1):29-37. PubMed ID: 32936235
[TBL] [Abstract][Full Text] [Related]
20. Assessment of Neurodevelopment in Infants With and Without Exposure to Asymptomatic or Mild Maternal SARS-CoV-2 Infection During Pregnancy.
Firestein MR; Shuffrey LC; Hu Y; Kyle M; Hussain M; Bianco C; Hott V; Hyman SP; Kyler M; Rodriguez C; Tejeda Romero M; Tzul Lopez H; Alcántara C; Amso D; Austin J; Bain JM; Barbosa J; Battarbee AN; Bruno A; Ettinger S; Factor-Litvak P; Gilboa S; Goldman S; Gyamfi-Bannerman C; Maniatis P; Marsh R; Morrill T; Mourad M; Muhle R; Newes-Adeyi G; Noble KG; O'Reilly KC; Penn AA; Reichle L; Sania A; Semenova V; Silver WG; Smotrich G; Tita AT; Tottenham N; Varner M; Welch MG; Zork N; Garey D; Fifer WP; Stockwell MS; Monk C; Dawood F; Dumitriu D
JAMA Netw Open; 2023 Apr; 6(4):e237396. PubMed ID: 37036706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
